Rapport Therapeutics registers up to $110M in at-the-market stock offering

Rapport Therapeutics, Inc.

Filed prospectus supplement on Jan 7, 2026 to sell up to $110M of common stock through Leerink and Cantor Fitzgerald.
Sales would be made under existing Sales Agreement dated July 1, 2025; no sales have occurred to date.
Legal opinion from Goodwin Procter LLP filed as Exhibit 5.1.
Offering is for general corporate purposes; no specific use of proceeds disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.